# Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)

Source: https://onco.cc/trials/nct04597671/  
OnCo record `nct04597671` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of durvalumab in lung cancer, run by Association NVALT Studies, active but no longer recruiting.

## Summary

Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28) is a phase 3, randomised interventional study registered as NCT04597671 by Association NVALT Studies, with a registry enrolment figure of 170 participants, started 2021-12-06 and due to reach its primary completion in 2028-12. Interventions recorded: Durvalumab; low-dose PCI. Conditions listed: Carcinoma, Non-Small-Cell Lung. Primary outcome: Reduction of incidence of brain metastases. Lung eligibility wording from the registry: "TNM8 stage IIIA, IIIB or IIIC non-small cell lung cancer before start of concurrent chemoradiotherapy (preferentially histology; cytology is allowed)". Sites: Netherlands. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-25
- Also known as: NVALT28
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT04597671
- Phase: 3
- Setting: NVALT 28/ PRL01 Durvalumab and Low-dose Prophylactic Cranial Irradiation (PCI) Versus Durvalumab and Observation in Radically Treated Patients With Stage III Non-small Cell Lung Cancer: A Phase III Randomized Study
- Sponsor: Association NVALT Studies
- Enrolled: 170

## Sources

- ClinicalTrials.gov NCT04597671: https://clinicaltrials.gov/study/NCT04597671

## Connected records

- cancers: [Unresectable stage III non-small-cell lung cancer](https://onco.cc/cancers/stage-iii-unresectable-nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04597671.json